Pidilizumab in the treatment of diffuse large B-cell lymphoma

Locke Johnson Bryan, Leo I. Gordon

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.

Original languageEnglish (US)
Pages (from-to)1361-1368
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume14
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Transplants
Hematologic Neoplasms
Hematopoietic Stem Cells
Stem cells
Cells
Disease-Free Survival
Expert Testimony
Therapeutics
Clinical Trials
pidilizumab

Keywords

  • Diffuse large B-cell lymphoma
  • Monoclonal antibody
  • Non-Hodgkin lymphoma
  • Pidilizumab
  • Programmed death-1

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Pidilizumab in the treatment of diffuse large B-cell lymphoma. / Bryan, Locke Johnson; Gordon, Leo I.

In: Expert Opinion on Biological Therapy, Vol. 14, No. 9, 01.01.2014, p. 1361-1368.

Research output: Contribution to journalReview article

@article{93a997077a9d4dc8a35567f4606356c3,
title = "Pidilizumab in the treatment of diffuse large B-cell lymphoma",
abstract = "Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.",
keywords = "Diffuse large B-cell lymphoma, Monoclonal antibody, Non-Hodgkin lymphoma, Pidilizumab, Programmed death-1",
author = "Bryan, {Locke Johnson} and Gordon, {Leo I.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/14712598.2014.942637",
language = "English (US)",
volume = "14",
pages = "1361--1368",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Pidilizumab in the treatment of diffuse large B-cell lymphoma

AU - Bryan, Locke Johnson

AU - Gordon, Leo I.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.

AB - Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.

KW - Diffuse large B-cell lymphoma

KW - Monoclonal antibody

KW - Non-Hodgkin lymphoma

KW - Pidilizumab

KW - Programmed death-1

UR - http://www.scopus.com/inward/record.url?scp=84905816355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905816355&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.942637

DO - 10.1517/14712598.2014.942637

M3 - Review article

C2 - 25056108

AN - SCOPUS:84905816355

VL - 14

SP - 1361

EP - 1368

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -